Innovative healthcare delivery for patients with asthma using digitally supported self-management: A pilot study in secondary care

Completed

Conditions: asthma
10006436

Registration Number: NL-OMON53444

Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 23

Inclusion Criteria

• Being aged 18 years or older
• Not having used Astmakompas before
• Having a physician diagnosis of asthma
• Having uncontrolled asthma as defined by a score of >= 1.5 on the Asthma
Control Questionnaire
• Being able to understand, read and speak the Dutch language (i.e., based on
self-report)
• Having access to the Internet and a smartphone

Exclusion Criteria

• Having a respiratory disease other than asthma
• Having a non-reversible airway obstruction

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary study parameters include the Feasibility of Intervention Measure (FIM),<br /><br>the Acceptability of Intervention Measure (AIM, only administered in HCPs),<br /><br>objective user patterns of Astmakompas, the Client Satisfaction Questionnaire-8<br /><br>(CSQ-8, only administered in patients), the System Usability Scale (SUS,<br /><br>administered in both HCPs and patients), and adverse events (assessed in<br /><br>patients). Qualitative assessment in patients and HCPs will give a more<br /><br>in-depth understanding of feasibility, acceptability, usability and safety of<br /><br>Astmakompas.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters, all assessed in patients, include asthma control<br /><br>(assessed using the Asthma Control Questionnaire [ACQ] and the weekly<br /><br>monitoring questionnaire that is part of Astmakompas), lung function as<br /><br>assessed by the spirometer, illness-related quality of life as assessed by the<br /><br>Respiratory Illness questionnaire-Monitoring 10 (RIQ-MON10), generic quality of<br /><br>life as assessed by the EuroQol 5 dimensions 5 levels (EQ-5D-5L), the Perceived<br /><br>Control of Asthma Questionnaire (PCAQ), and direct and indirect costs as<br /><br>assessed by items from the iMTA Productivity Cost Questionnaire (iPCQ) and iMTA<br /><br>Medical Consumption Questionnaire (iMCQ). Additionally, qualitative assessment<br /><br>in patients and HCPs will give a more in-depth understanding of direct and<br /><br>indirect costs. </p><br>